Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata

Journal of Dermatological Treatment

Volumn 30, Issue 6, 2019, Pages 588-593

  Rinaldi, Fabio ^a   Marzani, Barbara ^a   Pinto, Daniela ^a   Sorbellini, Elisabetta ^a  

^a International Hair Research Foundation   (Italy)

Author keywords

AA; alopecia areata; biomimetic peptides; PRP

Indexed keywords

ACETYL DECAPEPTIDE; BIOMIMETIC PEPTIDE; COPPER; COSMETIC; LACTOFERRIN; LACTOGLOBULIN; MELATONIN; OCTAPEPTIDE; OLIGOPEPTIDE; PLACEBO; RECOMBINANT GROWTH FACTOR; TRIPEPTIDE; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; PEPTIDE;

ADULT; ALOPECIA AREATA; ARTICLE; BIOTECHNOLOGY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; HAIR; MIDDLE AGED; PLACEBO EFFECT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ALOPECIA AREATA; BIOMIMETIC MATERIALS; COSMETICS; DOUBLE-BLIND METHOD; FEMALE; HAIR; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PLACEBO EFFECT; PLATELET-RICH PLASMA; TREATMENT OUTCOME;

EID: 85061028750     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546634.2018.1544405     Document Type: Article

References (85)

1. Syed SA, Sandeep S. Alopecia areata: a review. J Saudi Soc Dermatol Dermatol Surg. 2013;17:37–45.
2. D'Ovidio R. Alopecia Areata: news on diagnosis, pathogenesis and treatment. G Ital Dermatol Venereol. 2014;149:25–45.
3. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405–409.
4. Hordinsky M, Ericson M. Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73–78.
5. Brenner W, Diem E, Gschnait F. Coincidence of vitiligo, alopecia areata, onychodystrophy, localized scleroderma and lichen planus. Dermatologica. 1979;159:356–360.
6. Borde A, Åstrand A. Alopecia areata and the gut-the link opens up for novel therapeutic interventions. Expert Opin Ther Targets. 2018;22:503–511.
7. Rebello D, Wang E, Yen E. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J. 2017;13:e107.
8. Rinaldi F, Pinto D, Marzani B, et al. Human microbiome: what's new in scalp diseases. J Transl Sci. 2018;4:1–4.
9. Dawber R. Alopecia areata. Monogr Dermatol. 1989;2:89–102.
10. Tosti A, Iorizzo M, Botta GL, et al. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venerol. 2006;20:1243–1247.
11. Sardesai VR, Prasad S, Agarwal TD. A study to evaluate the efficacy of various topical treatment modalities for alopecia areata. Int J Trichol. 2012;4:265–270.
12. Kar BR, Handa S, Dogra S, et al. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol. 2005;52:287–290.
13. Takakura N, Yoshida H, Kunisada T, et al. Involvement of platelet-derived growth factor receptor-alpha in hair canal formation. J Invest Dermatol. 1996;107:770–777.
14. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409–417.
15. Rishikaysh P, Dev K, Diaz D, et al. Signaling Involved in hair follicle morphogenesis and development. Int J Mol Sci. 2014;15:1647–1670.
16. Jain R, De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets. 2014;18:787–806.
17. Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83:9–18.
18. Böhlen P, Esch F, Baird A, et al. Acidic fibroblast growth factor (FGF) from bovine brain: amino-terminal sequence and comparison with basic FGF. Embo J. 1985;4:1951–1956.
19. Kawano M, Komi-Kuramochi A, Asada M, et al. Comprehensive analysis of FGF and FGFR expression in skin: FGF18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles. J Invest Dermatol. 2005;124:877–885.
20. Kimura-Ueki M, Oda Y, Oki J, et al. Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling. J Invest Dermatol. 2012;132:1338–1345.
21. Mak KK, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem. 2003;278:26120–26126.
22. Rinaldi F, Sorbellini E, Bezzola P. The role of up-stimulation of growth factors in hair transplantation: improve the revascularization of transplanted hair growth mediated by angiogenesis. Forum. 2007;2.
23. Jungbluth P, Grassmann J-P, Thelen S, et al. Concentration of platelets and growth factors in platelet-rich plasma from Goettingen minipigs. GMS Interdisciplinar Plastic Reconstruct Surger DGPW. 2014;3:Doc11.
24. Kozlowska U, Blume-Peytavi U, Kodelja V, et al. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998;290:661–668.
25. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81:449–494.
26. du Cros DL. Fibroblast growth factor and epidermal growth factor in hair development. J Invest Dermatol. 1993;101:106S–113S.
27. Lin WH, Xiang LJ, Shi HX, et al. Fibroblast growth factors stimulate hair growth through β-catenin and Shh expression in C57BL/6 mice. Biomed Res Int. 2015;2015:730139.
28. Yoon SY, Kim K-T, Jo SJ, et al. Induction of hair growth by insulin-like growth factor-1 in 1,763 mhz radiofrequency-irradiated hair follicle cells. PLoS ONE. 2011;6:e28474.
29. Rossano F, Di Martino S, Iodice L, et al. Correlation between individual inflammation genetic profile and platelet rich plasma efficacy in hair follicle regeneration: a pilot study reveals prognostic value of IL-1a polymorphism. Eur Rev Med Pharmacol Sci. 2017;21:5247–5257.
30. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62:489–496.
31. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P–PRP) to leucocyte- and platelet-rich fibrin (LPRF). Trends Biotechnol. 2009;27:158–167.
32. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529–14535.
33. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, et al. Slow release of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin (PRF): A gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009;27:63–69.
34. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638–646.
35. Li ZJ, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38:1040–1046.
36. Alves R, Grimalt R. Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42:491–497.
37. Ferrari M, Zia S, Valbonesi M, et al. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987;10:47–50.
38. Anitua E, Sánchez M, Nurden AT, et al. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24:227–234.
39. Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37:2259–2272.
40. Mapar MA, Shahriari S, Haghighizadeh MH. Efficacy of platelet-rich plasma in the treatment of androgenetic (male-patterned) alopecia: a pilot randomized controlled trial. J Cosmet Laser Ther. 2016;18:452–455.
41. Cole JP, Cole MA, Insalaco C, et al. Alopecia and platelet-derived therapies. Stem Cell Investig. 2017;4:88.
42. Sorbellini E, Trink A, Rinaldi F. Experimental clinical assessment of the use of platelet-rich plasma in dermatology and rationale for its use in the treatment of non-scarring alopecia. Presented at the 35th La Medicina Estetica 4 October 2011.
43. Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169:690–694.
44. Giordano S, Romeo M, di Summa P, et al. A meta-analysis on evidence of platelet-rich plasma for androgenetic alopecia. Int J Trichology. 2018;10:1–10.
45. Reddy B, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012;21:563–568.
46. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4:16.
47. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22:207–218.
48. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31:327–345.
49. Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv. 2005;2:43–51.
50. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30:834–839.
51. Lee WJ, Sim HB, Jang YH, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016;28:438–443.
52. Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. Faseb J. 2004;18:385–387.
53. Philp D, St-Surin S, Cha HJ, et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95–103.
54. Ito C, Saitoh Y, Fujita Y, et al. Decapeptide with fibroblast growth factor (FGF)-5 partial sequence inhibits hair growth suppressing activity of FGF-5. J Cell Physiol. 2003;197:272–283.
55. Bassino E, Zanardi A, Gasparri F, et al. Effects of the biomimetic peptide Sh-Polypeptide 9 (CG-VEGF) on cocultures of human hair follicle dermal papilla cells and microvascular endothelial cells. Exp Dermatol. 2016;25:237–239.
56. Rinaldi F, Sorbellini E, Castiglioni M, et al. The role of mimicking growth factors to control anagen phase: evaluation in vitro and in vivo. JADD. 2010;62:AB74.
57. Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines–Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440–447.
58. Olsen E, Hordinsky M, McDonald-Hull S, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40:242–246.
59. Olsen EA. Investigative guidelines for alopecia areata. Dermatol Ther. 2011;24:311–319.
60. Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58:395–402.
61. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol. 2001;15:137–139.
62. Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Physician. 2017;96:371–378.
63. Singh S. Role of platelet-rich plasma in chronic alopecia areata: our centre experience. Indian J Plast Surg. 2015;48:57–59.
64. Munki T. Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: a case report. J Dermatol Dermatol Surg. 2016;20:87–90.
65. Garg S, Manchanda S. Platelet-rich plasma-an 'Elixir' for treatment of alopecia: personal experience on 117 patients with review of literature. Stem Cell Investig. 2017;4:64.
66. Greco J, Brandt R. The effects of autologous platelet rich plasma and various growth factors on non-transplanted miniaturized hair. Hair Transplant Forum Int. 2009;19:49–50.
67. Donovan J. Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP). J JAAD Case Rep. 2015;1:305–307.
68. El Taieb MA, Ibrahim H, Nada EA, et al. Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: a trichoscopic evaluation. Dermatol Ther. 2017;30:1–6.
69. Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238:343–346.
70. Pickart L, Downey D, Lovejoy S, et al. Gly-l-his-l-lys:copper(II)–A human plasma factor with superoxide dismutase-like and wound-healing properties, In: Superoxide and Superoxide Dismutase. Edit Rotilio, Amsterdam: Elsevier, 1986. p. 555–558.
71. Miller DM, DeSilva D, Pickart L, et al. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79–84.
72. Vinci C, Caltabiano V, Santoro AM, et al. Copper addition prevents the inhibitory effects of interleukin 1-beta on rat pancreatic islets. Diabetologia. 1995;38:39–45.
73. McCormack MC, Nowak KC, Koch RJ. The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model. Arch Facial Plast Surg. 2001;3:28–32.
74. Simeon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999;12:957–964.
75. Simeon A, Wegrowski Y, Bontemps Y, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115:962–968.
76. Simeon A, Emonard H, Hornebeck W, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;18:2257–2665.
77. Raju KS, Alessandri G, Gullino PM. Characterization of a chemoattractant for endothelium induced by angiogenesis effectors. Cancer Res. 1984;44:1579–1584.
78. Pickart L, New metal peptide complexes and derivatives used for stimulating growth of hair in warm-blooded animals, especially humans, US Patent 5,120,831; Compositions for stimulating hair growth containing cupric complexes of peptide derivatives including. glycyl-l-histidyl-l-lysine n-octyl ester. US Patent 5,177,061; New glycyl-histidyl-lysyl copper compounds used in stimulating hair growth; US Patent 5,214,032; Metal-peptide compositions and methods for stimulating hair growth, US Patent 5,550,183.
79. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993;101:143S–147S.
80. Chen P, Cescon M, Bonaldo P. Lack of collagen VI promotes wound-induced hair growth. J Invest Dermatol. 2015;135:2358–2367.
81. Matsumura H, Mohri Y, Binh NT, et al. Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis. Science. 2016;351:aad395.
82. Kruzel ML, Zimecki M, Actor JK, et al. Lactoferrin in a context of inflammation-induced pathology. Frontiers Immunol. 2017;8:1438.
83. Zhang K, Letham DS, John PC. Cytokinin controls the cell cycle at mitosis by stimulating the tyrosine dephosphorylation and activation of p34cdc2-like H1 histone kinase. Planta. 1996;200:2–12.
84. Tai CS, Chen YY, Chen WL. β-lactoglobulin influences human immunity and promotes cell proliferation. BioMed Res Int. 2016;2016:1.
85. Geyfman M, Andersen B. Clock genes, hair growth and aging. Aging (Albany NY). 2010;2:122–128.